Shimon Sakaguchi

Shimon Sakaguchi is a 2025 Nobel Laureate in Physiology or Medicine and the founding father of regulatory T cell biology — one of the most consequential fields in modern immunology. A Distinguished Professor at the Immunology Frontier Research Center (IFReC) at Osaka University and Professor Emeritus of Kyoto University, Sakaguchi holds an MD and PhD from Kyoto University and conducted formative postdoctoral research at Johns Hopkins University and Stanford University as a Lucille P. Markey Scholar. He later served as Assistant Professor of Immunology at the Scripps Research Institute before returning to Japan, where he has led landmark research programs for more than three decades.

Nobel Prize speaker Shimon Sakaguchi is best known for a discovery he made in 1995 that fundamentally reshaped immunological science: the identification of regulatory T cells (Tregs), a previously unknown class of immune cells whose sole function is to prevent the immune system from attacking the body’s own tissues. At a time when the scientific consensus held that immune tolerance was maintained exclusively through the elimination of harmful cells in the thymus, Sakaguchi challenged the prevailing view and demonstrated that a second, peripheral layer of immune control existed. His 1995 paper — showing that a specific subset of CD4+ T cells marked by the CD25 receptor actively suppressed autoimmune responses — is now regarded as one of the most cited and transformative publications in the history of immunology. In 2003, his laboratory proved that FOXP3, the gene co-discovered by Mary Brunkow and Fred Ramsdell, encodes the master transcription factor governing Treg identity and function — completing the molecular picture of peripheral immune tolerance.

A Career of Firsts, Prizes, and Active Research

Sakaguchi’s recognition extends across the most prestigious honors in the life sciences. He is a recipient of the William B. Coley Award, the Canada Gairdner International Award, the Crafoord Prize in Polyarthritis, the Paul Ehrlich and Ludwig Darmstaedter Prize, and the Robert Koch Prize, among many others. He was elected a Foreign Member of the National Academy of Sciences of the USA and received the Order of Culture — the highest accolade bestowed upon scholars in Japan. Remarkably, his scientific output has not slowed since the Nobel announcement: in October 2025, his laboratory published two papers in Science Translational Medicine demonstrating a breakthrough technique for converting disease-causing T cells into regulatory T cells without genome editing — a potential path to treating autoimmune diseases including ALS, arthritis, and inflammatory conditions. He also advises Coya Therapeutics, a clinical-stage biotech developing Treg-activating biologics for ALS and other neurodegenerative diseases.

As a speaker, Shimon Sakaguchi offers audiences something extraordinarily rare: the direct perspective of the scientist who discovered the immune system’s internal peacekeepers, told across a lifetime of inquiry that ran counter to scientific consensus before transforming it. His talks illuminate how immune tolerance works, what happens when it fails, and how the regulatory T cell field is now reshaping cancer immunotherapy, autoimmune treatment, and transplant medicine worldwide. For scientific, medical, biotech, and innovation audiences, Sakaguchi embodies the power of intellectual courage and long-horizon thinking in science.